232 related articles for article (PubMed ID: 31136212)
1. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
[No Abstract] [Full Text] [Related]
2. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
[TBL] [Abstract][Full Text] [Related]
3. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
[TBL] [Abstract][Full Text] [Related]
5. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
Kim H; Kim J; Byeon S; Jang KT; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
Oncology; 2021; 99(6):365-372. PubMed ID: 33730723
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
Valle JW; Furuse J; Jitlal M; Beare S; Mizuno N; Wasan H; Bridgewater J; Okusaka T
Ann Oncol; 2014 Feb; 25(2):391-8. PubMed ID: 24351397
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
[TBL] [Abstract][Full Text] [Related]
11. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; André T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater J; Valle JW
J Hepatol; 2020 Nov; 73(5):1109-1117. PubMed ID: 32446715
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
13. R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer.
Matull WR; Dhar DK; Ayaru L; Sandanayake NS; Chapman MH; Dias A; Bridgewater J; Webster GJ; Bong JJ; Davidson BR; Pereira SP
Liver Int; 2011 Jan; 31(1):99-107. PubMed ID: 20846273
[TBL] [Abstract][Full Text] [Related]
14. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study.
Kato A; Shimizu H; Ohtsuka M; Yoshidome H; Yoshitomi H; Furukawa K; Takeuchi D; Takayashiki T; Kimura F; Miyazaki M
Ann Surg Oncol; 2013 Jan; 20(1):318-24. PubMed ID: 23149849
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
16. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
[TBL] [Abstract][Full Text] [Related]
17. Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010-2016.
Wang J; Bo X; Nan L; Wang CC; Gao Z; Suo T; Ni X; Liu H; Lu P; Wang Y; Liu H
Cancer Med; 2020 Feb; 9(4):1335-1348. PubMed ID: 31876990
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
[TBL] [Abstract][Full Text] [Related]
19. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
Meyerhardt JA; Zhu AX; Stuart K; Ryan DP; Blaszkowsky L; Lehman N; Earle CC; Kulke MH; Bhargava P; Fuchs CS
Dig Dis Sci; 2008 Feb; 53(2):564-70. PubMed ID: 17597402
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
